Header

UZH-Logo

Maintenance Infos

Epidemiology and Clinical Impact of Glycopeptide Resistance in Staphylococcus aureus


Ruef, C (2004). Epidemiology and Clinical Impact of Glycopeptide Resistance in Staphylococcus aureus. Infection, 32(6):315-327.

Abstract

Staphylococcus aureus with resistance to glycopeptide antibiotics has been considered to be a rare cause of clinically relevant infections. A review of the current literature shows that this is indeed the case for infections caused by S. aureus with high-level resistance to vancomycin (VRSA), as only isolated cases have been reported. VRSA develops following the insertion of the vanA gene, which is transferred from enterococci with vancomycin resistance. On the other hand, infections caused by S. aureus with intermediate resistance to glycopeptides (VISA), or heterogeneously expressed intermediate level glycopeptide resistance (hVISA), are more common. These infections are associated with clinical failure of glycopeptide therapy. While the biochemical and phenotypic features including a thickened cell wall of hVISA and VISA are well known, the genetic basis of these phenotypes remains unknown. Certain genetic regulatory elements such as agr II are associated with reduced susceptibility of S. aureus to glycopeptides. Available data suggest that certain infections might be successfully treated using higher doses of vancomycin. However, as treatment failure is particularly common in infections with a high bacterial load, it may be necessary to resort to other antibiotics such as linezolid, often combined with surgical intervention, in order to successfully treat these infections. Open questions regarding diagnosis, pathogenesis, epidemiology, and treatment of glycopeptide resistance in S. aureus are addressed in this review. Clinicians should be aware of these aspects, since S. aureus remains one of the most important bacteria in modern medicine

Abstract

Staphylococcus aureus with resistance to glycopeptide antibiotics has been considered to be a rare cause of clinically relevant infections. A review of the current literature shows that this is indeed the case for infections caused by S. aureus with high-level resistance to vancomycin (VRSA), as only isolated cases have been reported. VRSA develops following the insertion of the vanA gene, which is transferred from enterococci with vancomycin resistance. On the other hand, infections caused by S. aureus with intermediate resistance to glycopeptides (VISA), or heterogeneously expressed intermediate level glycopeptide resistance (hVISA), are more common. These infections are associated with clinical failure of glycopeptide therapy. While the biochemical and phenotypic features including a thickened cell wall of hVISA and VISA are well known, the genetic basis of these phenotypes remains unknown. Certain genetic regulatory elements such as agr II are associated with reduced susceptibility of S. aureus to glycopeptides. Available data suggest that certain infections might be successfully treated using higher doses of vancomycin. However, as treatment failure is particularly common in infections with a high bacterial load, it may be necessary to resort to other antibiotics such as linezolid, often combined with surgical intervention, in order to successfully treat these infections. Open questions regarding diagnosis, pathogenesis, epidemiology, and treatment of glycopeptide resistance in S. aureus are addressed in this review. Clinicians should be aware of these aspects, since S. aureus remains one of the most important bacteria in modern medicine

Statistics

Citations

Dimensions.ai Metrics
58 citations in Web of Science®
59 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

32 downloads since deposited on 19 Oct 2018
14 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Microbiology (medical)
Health Sciences > Infectious Diseases
Language:English
Date:1 December 2004
Deposited On:19 Oct 2018 07:59
Last Modified:15 Apr 2021 14:52
Publisher:Springer
ISSN:0300-8126
OA Status:Green
Publisher DOI:https://doi.org/10.1007/s15010-004-4124-7

Download

Green Open Access

Download PDF  'Epidemiology and Clinical Impact of Glycopeptide Resistance in Staphylococcus aureus'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 428kB
View at publisher